Functional characterisation of the regulation of CAAT enhancer binding protein alpha by GSK-3 phosphorylation of Threonines 222/226

H-K Liu1,4, S Perrier1, C Lipina2, D Finlay2, H McLauchlan3, CJ Hastie3, HS Hundal1 and C Sutherland*2

Address: 1Division of Molecular Physiology, School of Life Sciences, University of Dundee, Dundee, DD1 4HN, UK, 2Division of Pathology and Neurosciences, Ninewells Medical School, University of Dundee, Dundee, DD1 9SY, UK, 3Division of Signal Transduction and Therapy, School of Life Sciences, University of Dundee, Dundee, DD1 4HN, UK and 4National Research Institute of Chinese Medicine, Taipei, Taiwan, Republic of China

Email: H-K Liu - hk.liu@nricm.edu.tw; S Perrier - s.perrier@dundee.ac.uk; C Lipina - c.lipina@dundee.ac.uk; D Finlay - d.finlay@dundee.ac.uk; H McLauchlan - h.j.mclauchlan@dundee.ac.uk; CJ Hastie - c.j.hastie@dundee.ac.uk; HS Hundal - h.s.hundal@dundee.ac.uk; C Sutherland* - c.d.sutherland@dundee.ac.uk

* Corresponding author

Published: 06 April 2006

Abstract

Background: Glycogen Synthase Kinase-3 (GSK3) activity is repressed following insulin treatment of cells. Pharmacological inhibition of GSK3 mimics the effect of insulin on Phosphoenolpyruvate Carboxykinase (PEPCK), Glucose-6 Phosphatase (G6Pase) and IGF binding protein-1 (IGFBP1) gene expression. CAAT/enhancer binding protein alpha (C/EBPα) regulates these gene promoters in liver and is phosphorylated on two residues (T222/T226) by GSK3, although the functional outcome of the phosphorylation has not been established. We aimed to establish whether CEBPα is a link between GSK3 and these gene promoters.

Results: C/EBPα represses the IGFBP1 thymine-rich insulin response element (TIRE), but mutation of T222 or T226 of C/EBPα to non-phosphorylatable alanines has no effect on C/EBPα activity in liver cells (towards the TIRE or a consensus C/EBP binding sequence). Phosphorylation of T222/T226 is decreased by GSK3 inhibition, suggesting GSK3 does phosphorylate T222/226 in intact cells. However, phosphorylation was not altered by treatment of liver cells with insulin. Meanwhile C/EBPα activity in 3T3 L1 preadipocytes was enhanced by mutation of T222/T226 and/or S230 to alanine residues. Finally, we demonstrate that C/EBPα is a very poor substrate for GSK3 in vitro and in cells.

Conclusion: The work demonstrates an important role for this domain in the regulation of C/EBPα activity in adipocytes but not hepatocytes, however GSK3 phosphorylation of these residues does not mediate regulation of this C/EBP activity. In short, we find no evidence that C/EBPα activity is regulated by direct phosphorylation by GSK3.
Background
Glycogen synthase kinase-3 (GSK3), an insulin-inhibited protein kinase, has been linked to the control of many cellular processes [1]. It was originally identified as the protein kinase that phosphorylated and inactivated glycogen synthase in rabbit muscle [2]. Two highly related forms of GSK3 (GSK3α and GSK3β) are expressed from distinct genes [3,4]. They share greater than 95% identity in their kinase domains and appear to be ubiquitously expressed in mammals [3,4]. In resting cells GSK3 activity is high and inhibition of the kinase is achieved by at least two mechanisms, firstly through phosphorylation of an N-terminal serine residue (Ser-21 in GSK3α, Ser-9 in GSK3β) [5,6], and secondly through protein-protein interaction [7]. Insulin promotes the phosphorylation of Ser-9/21 of GSK3 by activation of protein kinase B (PKB, also known as c-AKT) [8], while canonical Wnt signalling inhibits GSK3 independently of this N-terminal phosphorylation [9].

In liver, inhibition of GSK3 reduces expression of the Phosphoenolpyruvate Carboxykinase (PEPCK) and Glucose-6 Phosphatase (G6Pase) genes, two rate limiting enzymes in hepatic glucose production [10], as well as the IGF binding protein-1 (IGFBP1) gene [11]. These gene promoters share a related DNA sequence termed the thymine-rich insulin response element (TIRE) that plays an important role in their response to insulin [12-14]. Expression of these genes as well as GSK3 activity is abnormally high in insulin resistant states such as Type 2 diabetes mellitus (T2DM) [15-19]. Meanwhile overexpression of GSK3 antagonises insulin regulation of IGFBP1 [11]. Therefore inhibition of GSK3 is proposed as a potential target for the treatment of T2DM [1,20,21]. Indeed selective GSK3 inhibitors significantly reduce hepatic glucose output and blood glucose levels in several animal models of obesity and diabetes [22-25]. However, GSK3 is reported to have over 30 substrates, and mutation of one of these, APC, is linked to the development of colonic cancer [20,21,26]. In addition, genetic deletion of one of the isoforms (GSK3β) leads to liver cell death, possibly due to increased sensitivity to TNFα [27]. Hence great care and consideration is being given to the development of GSK3 inhibitors for use in humans. With this in mind we have initiated a search for molecules that link GSK3 to the gluconeogenic gene promoters and in particular the TIRE, since inhibition of GSK3 is sufficient to repress the isolated DNA element [11]. Identification of the GSK3 substrate(s) that regulates IGFBP1, G6Pase and PEPCK gene expression, may permit manipulation of this specific interaction without affecting other GSK3 targets, thereby reducing potential side effects. GSK3 is an unusual kinase in that most substrates must be phosphorylated (primed) on a Ser/Thr four or five residues C-terminal to the GSK3 target residue [11] for review. Priming of the substrate is performed by a distinct protein kinase, therefore inhibition of the priming kinase indirectly inhibits GSK3 regulation of the substrate, but only those substrates primed by that particular priming kinase. Priming kinases are potential targets for more specific interference with GSK3 function.

The basic leucine zipper transcription factor, CAAT-enhancer binding protein alpha (C/EBPα) is a potential link between GSK3 and the gluconeogenic genes based on the following information in the literature; 1) C/EBPα is phosphorylated on two residues (T222 and T226, numbers refer to rodent sequence) by GSK3, although the functional effect of phosphorylation is not yet clear [28], 2) C/EBPα is a key molecule in the regulation of the PEPCK and G6Pase gene promoters by cAMP [29-33] and T3 [34], 3) C/EBPα is regulated by wnt [35] and insulin [36,37] in brown adipocytes, and the insulin regulation involves PKB (a regulator of GSK3) [37], 4) PEPCK and G6Pase expression, as well as glucose and glycogen metabolism is abnormal in animals lacking C/EBPα [38-40] and 5) binding of a TIRE-interacting protein is blocked using an oligonucleotide representing a known C/EBPα binding sequence [41]. Therefore, we attempted to determine whether C/EBPα could modulate the activity of the isolated TIRE, or the gene promoters of interest, in a GSK3 regulated manner. In addition, although T222/T226 of C/EBPα were identified as targets for GSK3 it has not previously been established whether S230 was a target for a ‘priming’ kinase, so we have also investigated whether mutation of S230 influences C/EBPα regulation.

Results and discussion
C/EBPα regulates the TIRE independently of T222/226 phosphorylation
We have previously shown that insulin, or pharmacological inhibition of GSK3, reduced the expression of endogenous PEPCK, G6Pase and IGFBP1 genes and also the activity of the isolated thymine-rich insulin response element (TIRE) found in these gene promoters [10,11]. In an attempt to further characterise the GSK3 regulation of PEPCK, G6Pase and IGFBP1 we assessed whether a target for GSK3, namely C/EBPα, could regulate TIRE activity. In the hepatocyte C/EBPα activity is linked to cAMP induction of genes, so insulin inhibition of C/EBPα could explain repression of these genes by insulin. In this model, phosphorylation of C/EBPα by GSK3 would have to induce C/EBPα activity toward the TIRE. Interestingly, C/EBPα overexpression had a repressive effect on TIRE activity in the rat hepatoma H4IIIE cells (Fig 1A), and the repression was lost when the TIRE sequence was mutated at two residues to produce an insulin insensitive sequence (DM5 [42]; Fig 1A). Hence C/EBPα regulated the TIRE in
Phosphorylation of the TIRE, and that the overexpressed C/EBPα, altered the ability of C/EBPα to repress TIRE activity (Fig 1B). Unfortunately, increased GSK3 activity also blocked the repressive action of the C/EBPα-AAA (Fig 1B) clearly demonstrating that phosphorylation of T222/T226/S230 was not required for the action of GSK3 on the isolated TIRE in H4IIE cells. This data questioned the functional importance of T222/T226 phosphorylation in the regulation of C/EBPα activity.

Figure 1
C/EBPα expression suppresses the BPI-TIRE-Luc reporter activity in H4IIE cells, independently of the phosphorylation status of T222/T226. (A) H4IIE cells were transfected with BPI-TIRE-Luc (10 µg) or DM5-Luc (10 µg) along with either pcDNA6 vector (1 µg), Flag-C/EBPα (1 µg) or Flag-C/EBPα-AAA (1 µg). Subsequently, cells were incubated with or without 10 nM insulin for 20 h prior to lysis and luciferase assay. Results are presented as relative luciferase activity to the control (serum free) and are average ± SEM (n = 3) from two independent experiments. (B) H4IIE cells were infected with adenovirus expressing either β-Galactosidase (Ad-βgal) or active GSK3β (Ad-GSK3 S9A) for 20 h prior to transfection as described in (A). Results are presented as relative luciferase activity to the control (serum free) and are average ± SEM (n = 6) from two independent experiments. *** p < 0.001 compared to control (ad-b-gal).

Figure 2
C/EBPα phosphorylation in intact cells. AD293 cells were transiently transfected with Flag-C/EBPα (10 µg) prior to incubation with CHIR99021 as indicated (A). Cell lysates were then subjected to Western Blotting with the antibodies as labelled. A representative immunoblot (of three separate experiments) is given. (B) AD293 cells were transfected with Flag-C/EBPα (10 µg) plus GSK3α-V5 (10 µg) or pcDNA6 (10 µg) prior to 24 h incubation with CHIR99021 (2 µM), lysis and Western Blot analysis. A representative immunoblot (of three separate experiments) is given. (C) H4IIE cells were infected with adenovirus expressing Flag-C/EBPα. After 16 h the infected cells were serum starved for 3 h prior to incubation with or without insulin (10 nM) or CHIR99021 (2 µM) for the times indicated. Cell lysates were immunoblotted with the antibodies indicated and a representative experiment is provided.

The TIRE (Fig 1B). Unfortunately, increased GSK3 activity also blocked the repressive action of the C/EBPα-AAA (Fig 1B) clearly demonstrating that phosphorylation of T222/T226/S230 was not required for the action of GSK3 on the isolated TIRE in H4IIE cells. This data questioned the functional importance of T222/T226 phosphorylation in the regulation of C/EBPα activity.
**GSK3 phosphorylates C/EBPα in intact cells**

It was therefore important to establish whether T222 and T226 were actually phosphorylated by GSK3 in intact cells. Cells were transfected with wild-type and mutant C/EBPα and total and phosphorylated C/EBPα visualised by Western Blotting. T222/226 phosphorylation, measured with this antibody, was clearly present in intact cells (Fig 2). Incubation with 1 or 2 µM of the GSK3 inhibitor CHIR99021 [11,43] for 6 or 24 h significantly reduced the phosphorylation of T222/226 of wild-type C/EBPα (Fig 2A), confirming that GSK3 was a T222/226 kinase in these cells. At shorter incubations, 1 µM CHIR99021 was sufficient to give maximal reduction in T222/226 phosphorylation, while 2 µM had a greater effect at 24 h incubation. This is similar to the effect of these concentrations on β-catenin activation in the H4IIE cells [11]. Meanwhile, co-expression of active GSK3α (Fig 2B) only produced a marginal induction of phosphorylation (around 1.2 fold) suggesting that the expressed C/EBPα was either almost fully phosphorylated at T222/226 or that it was not a particularly good substrate for GSK3. Mutation of T222/226 to alanines made the mutant C/EBPα unresponsive to the phosphospecific antibody (see later). Interestingly, the dephosphorylation of C/EBPα in H4IIE cells treated with CHIR99021 was rapid, but not complete (Fig 2C). However, there was no significant reduction in T222/226 phosphorylation following up to 2 h incubation with insulin (Fig 2C and Fig 3), even though insulin promoted phosphorylation of Ser9/Ser21 of GSK3β and GSK3α respectively. Insulin reduced GSK3 activity around 50% in the H4IIE cell line but this is clearly not sufficient to reduce T222/226 phosphorylation. Therefore it appears that insulin does not regulate T222/226 phosphorylation in these cells through inhibition of GSK3. However, the data suggested that some level of T222/226 phosphorylation by GSK3 occurs on the overexpressed protein (Fig 2C).

**Figure 3**
Quantification of three experiments performed as in Fig 2C. Results are the average ± SEM.

**Figure 4**
C/EBPα phosphorylation in vitro. (A) Recombinant Flag-C/EBPα (6 pmol) was generated by scission of the GST-C/EBPα fusion protein and incubated with either recombinant GSK3β (2 U/ml) or p42 MAPK (10 U/ml) and [γ-32P]-ATP for 1, 10, 30, and 60 min. The reaction was stopped and separated by SDS-PAGE. (B) The stoichiometry of Flag-C/EBPα phosphorylation in (A) by either MAPK or GSK3β is quantified and presented. (C) GST-C/EBPα (7.5 pmol) was incubated with recombinant GSK3β (2 U/ml) and ATP for 1, 10, 30, and 60 min. The reaction was stopped and separated by SDS-PAGE and subjected to Western Blot analysis for phospho-T222/226. The equivalent stoichiometry of phosphorylation (mol/mol) calculated in A is indicated above each band.
C/EBPα is a relatively poor substrate for GSK3 in vitro

We next characterised C/EBPα phosphorylation by GSK3 in vitro (Fig 4). Incubation of C/EBPα with GSK3β for up to one hour resulted in a slow incorporation of less than 0.03 mol phosphate per mol of protein (Fig 4A and 4B). In comparison, p42MAP kinase phosphorylation of C/EBPα increased over 60 min peaking around 1.5 mol per mol (Fig 4A and 4B). Phosphorylation of C/EBPα by p42MAP kinase did not occur at T222, T226 or S230 (see below) and is more likely to be on S21 [44]. Interestingly western blot analysis of C/EBPα following incubation with GSK3β gave little indication of this slow increase in phosphorylation, and a very strong signal was obtained with the phosphospecific antibody even at low stoichiometry of phosphorylation (Fig 4C). These data demonstrated that C/EBPα was a relatively poor substrate for GSK3 in vitro, but that the phospho-T222/226 antibody was highly sensitive. It is difficult to directly compare phosphorylation of C/EBPα with other substrates of GSK3 as most are poorly phosphorylated prior to priming. For example CRMP phosphorylation by GSK3 (under identical conditions to those used for C/EBPα in Fig 4) incorporates around 0.2 mol/mol phosphate within 2 h of incubation [45]. However, this increases more than 5-fold if the substrate is first primed. Of course we can never rule out the possibility that an intrinsic factor improves the GSK3-C/EBPα interaction in vivo, either promoting priming at an unidentified residue or allowing greater phosphorylation by GSK3.

GSK3 phosphorylation of T222/226 in cells does not require S230 phosphorylation

Many substrates of GSK3 are primed for kinase recognition by prior phosphorylation at a S/T residue four amino acids C-terminal to the target site [1]. S230 lies within this ‘consensus’ GSK3 targeting sequence (Table 2). Therefore S230 phosphorylation could prime for T226 phosphorylation by GSK3, permitting subsequent phosphorylation of T222 by GSK3. However, mutation of S230 to alanine had no effect on T222/226 phosphorylation in intact cells (Fig 5). This argued that S230 phosphorylation did not prime for T226 phosphorylation by GSK3 in resting cells, or that the wild-type C/EBPα is not being efficiently phosphorylated at S230. Since the amino acid immediately following S230 is a proline (Table 2), we hypothesised that priming may only occur after induction of a proline-directed kinase such as a member of the MAP kinase family. Therefore we attempted to induce S230 phosphorylation by incubation of cells with serum, which stimulates the classical MAP kinase and several other proline-directed kinases such as cyclin-dependent kinases. However, T222/226 phosphorylation of wild-type or S230A C/EBPα was not altered in serum treated cells (Fig 5B), despite activation of the p90RSK downstream of the p42/p44MAP kinase (Fig 5B). This demonstrated we could not alter S230 phosphorylation by incubating cells with or without serum. Interestingly, serum treatment induced phosphorylation of S21/9 of GSK3α/β (Fig 5B), suggesting some inhibition of GSK3 occurs in the serum treated cells. This was not sufficient to reduce C/EBPα phosphorylation but did partially reduce glycogen synthase phosphorylation (a known substrate of GSK3 [146]; Fig 5B). Similarly, treatment of the cells with CHIR99021 did not completely inhibit T222/226 phosphorylation (Fig 2 and Fig 3), despite a complete loss of glycogen synthase phosphorylation (Fig 5B). Therefore T222/226 must be rela-

Table 1: Primers and oligonucleotides used in C/EBPα mutagenesis. Primers and oligonucleotides

| Constructs | DNA sequences |
|------------|---------------|
| Flag-C/EBPα | Forward: 5'-GGA TCC GCC ACC ATG GAC GAC GAT GAC AAG GAG TCG GCC GAC TTC TAC GAG-3' |
| S230A Flag-C/EBPα mutant | Forward: 5'-GGC CAC CCT GCG CCG CCG CCG GCG CCC GTG CCC AGC CCT CAT CCC-3' |
| Flag-C/EBPα mutant (AA) | Forward: 5'-GGA TCC GCC ACC ATG AGC GGC GGC GGG CCT T-3' |
| CBE-Luc reporter | Sense: 5'-CGG GAT GAG GCT GGG CAC GGG CGC CGG CGG CGG CGG AGG GTG GCC-3' |

Table 2: Comparison of mouse, rat and human C/EBPα sequences surrounding potential GSK3 target residues.

| Numbers refer to mouse (upper) and human (lower) potential phosphorylated residues. C/EBPα sequences. | |
|---|---|
| 222 226 230 | |

| Mouse | PHHTTPPTVPSHAA |
| Rat | PHHTTPPTVPSHPA |
| Human | PHHTTPPTVPSHAAA |

226 230 234
tively resistant to dephosphorylation or a distinct T222/226 protein kinase must be present in these cells. Again, potential substrates for GSK3 have been reported that have their priming at a residue more distant from the GSK3 target site, and we cannot discount that possibility. However, our data strongly argues against priming through S230 phosphorylation.

Prephosphorylation of CEBPα by p42 MAP kinase did not prime for subsequent phosphorylation by GSK3 in vitro (Fig 6A), confirming that S230 is not targeted by p42 MAP kinase. Similarly, incubation of cells with either a p42MAP kinase inhibitor (PD98059) or a p38MAP kinase inhibitor (SB203580) had no effect on phosphorylation of CEBPα at T222/226 (Fig 6B).

C/EBPα induced a consensus binding element while repressing the TIRE in H4IIE cells

In contrast to the repressive action on TIRE activity, over-expression of C/EBPα in H4IIE cells induced the activity of a consensus C/EBP binding element (CBE) (Fig 7A). We were therefore able to investigate whether the GSK3 regulation of T222/T226 was dependent on the DNA sequence analysed. Mutation of T222/226/S230 to alanines (in any combination) made no difference to the induction of the CBE by C/EBPα (Fig 7A). Similarly, inhibition of GSK3 using CHIR99021 or insulin had no effect on CBE activity (Fig 7A and 7B). Therefore GSK3 phosphorylation of T222/226 does not regulate either induction of the CBE or...
repression of the TIRE in the H4IIE cells. Interestingly CBE activity was induced in the presence of the synthetic glucocorticoid dexamethasone to a similar level as that seen with C/EBPα overexpression (Fig 7B).

C/EBPα overexpression does not regulate endogenous TIRE-containing genes

In order to establish whether changes in C/EBPα phosphorylation could alter expression of the insulin regulated genes IGFBP1 and G6Pase, we overexpressed C/EBPα in H4IIE cells using an adenoviral vector to produce almost 100% transfection efficiency (Figs 8, 9, 10). We observed no effect of C/EBPα expression on IGFBP1 (Fig 8) or G6Pase (Fig 9) gene expression, and no alteration in regulation of either gene by dexamethasone, insulin or CHIR99021. However, there was a significant repression of the co-expressed BP1-TIRE by C/EBPα when compared with the insulin resistant TIRE (DM5) (Fig 10). This suggests that C/EBPα overexpression represses the isolated element but has no effect on this element when it is in the context of the intact gene promoters. This is an example of the dangers of studying isolated promoter elements and extrapolating to intact gene promoters without examining endogenous regulation. Interestingly, a postnatal knockout of C/EBPα resulted in reduced basal expression of PEPCK and G6Pase but did not alter regulation of these genes by cAMP [40]. Again,
this would argue against a repressive effect of this factor on the endogenous genes.

**C/EBPα regulation of the CBE in preadipocytes is greater when T222/226 are mutated**

C/EBPα has an important role in adipocyte differentiation [37,47,48], therefore we transfected 3T3-L1 preadipocytes with C/EBPα and measured CBE activity (Fig 11A). In contrast to the H4IIE cells, mutation of T222/226 to alanines resulted in a significant increase in transactivation potential compared to wild-type C/EBPα (Fig 11A). This suggested that phosphorylation of these residues was inhibiting C/EBPα activity in these cells. Consistent with this hypothesis, inhibition of GSK3 using CHIR99021 or insulin induced wild-type C/EBPα activity (Fig 11A). In addition, the C/EBPα S230A mutant had similar transactivation potential to the AA mutant (Fig 11A), strongly suggesting that S230 was a priming site for T222/T226 phosphorylation in these cells. However we could find no evidence that phosphorylation of T222/226 was reduced in the S230A mutant (Fig 11B). Although there was a great deal of inter-experiment variation in the phosphorylation of T222/T226 in the WT and the S230A mutant there was not a significant difference between the two, and in 2 out of the three experiments the S230A mutant exhibited higher phosphorylation than the WT protein (Fig 11B). Therefore, changes in phosphorylation of these two sites cannot account for the difference in C/EBPα activity when the S230 site is mutated to alanine. Ideally it would be beneficial to confirm these data on endogenous gene expression in the adipocyte cell line, however these cells do not transfect efficiently with the adenoviral constructs making it impossible to examine their effect on endogenous genes.

**Conclusion**

In summary, C/EBPα is not the link between GSK3 and the hepatic TIRE-containing gene promoters. However, C/EBPβ can regulate the TIRE, at least when overexpressed, and the residues T222/226 and S230 all influence C/EBPα function in preadipocytes. Interestingly we demonstrate opposite effects of C/EBPα overexpression on TIRE and CBE activity, and a tissue specific role for the T222/226 motif in this activity. Our data also provides further evidence of the differences in transcription factor activity when measured using isolated promoter elements as opposed to intact gene promoters. During the course of this study a regulation of C/EBPβ by GSK3 in adipocytes
was reported [49]. Therefore it will be of interest to confirm whether this C/EBP isoform is the link between GSK3 inhibition and TIRE regulation in hepatocytes.

Methods

Material

Radioisotopes [γ-32P]ATP (Amersham Biosciences, Inc., Little Chalfont, Buckinghamshire, UK) and [α-32P]UTP (ICN, Thame, Oxfordshire, UK) were purchased from the indicated sources. Insulin was obtained from Novo Nordisk (Crawley, West Sussex, UK), dexamethasone and IBMX (Sigma, Poole, Dorset, UK), RNase Protection Assay Kit II was from AMS Biotech/Ambion (Austin, TX, USA). CHIR99021 was synthesised by Dr Rudolpho Marquez [11]. Antibodies to the following epitopes were purchased from the companies in parenthesis; C/EBPα (Santa Cruz Biotechnologies, UK), phospho-C/EBPα (T222/226) and phospho-GSK3α/β (S21/9) (Cell Signaling Technologies, Hertfordshire, UK), Flag (Sigma, Poole, Dorset, UK), while the Glycogen Synthase (total and site 3 phospho antibody), and p90 RSK phospho antibody were made in the Division of Signal Transduction Therapy, University of Dundee.

Cell culture

The rat hepatoma cell line H4IIE was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 1000 mg/L glucose, 5% (v/v) foetal calf serum (GIBCO, Carlsbad, CA). The AD293 cell line was maintained in DMEM containing 4500 mg/L glucose, 10% (v/v) foetal calf serum, while 3T3-L1 preadipocytes were grown in DMEM containing 4500 mg/L glucose and 10% (v/v) newborn calf serum (GIBCO).

Construction of plasmid DNA, luciferase reporter, and mutagenesis

The full length C/EBPα cDNA was amplified by PCR from a rat L6 cDNA library and BamHI/Kosac/Flag and EcoRI sequences introduced at the 5’ and 3’ end respectively as indicated in Table 1. The PCR product was subcloned into TOPO one shot (Invitrogen), verified by DNA sequencing, and subcloned into pcDNA6, GST-pGEX-6, and psslutte-CMV vectors for the purpose of expression in mammalian cells, production of recombinant GST-tagged protein in Escherichia coli BL21 cells, and construction of recombinant adenovirus (AdEasy XL Adenoviral Vector System, Stratagene), respectively. Flag-C/EBPα point mutants, S230A, T222A/T226A (AA), and T222A/T226A/S230A (AAA) were generated using the QuickChange mutagenesis kit (Stratagene) with the oligo sequences shown in Table 1. The AAA mutant was generated by introducing the S230A point mutation into the AA mutant. A luciferase reporter construct containing a C/EBP consensus binding sequence (CBE-Luc) 5’ of a thymidine kinase promoter was constructed using the oligos shown in Table 1. Both sense and antisense oligos were annealed prior to restriction digest with Kpnl and Bgl II. The product was subcloned into the BP1 luciferase reporter linearised with Kpnl and BamHI to remove the TIRE (the luciferase con-
struct was a gift from Dr Robert Hall and Professor Daryl K. Granner (Vanderbilt University, TN, USA)).

**Transient transfection**

AD293 cells were transiently transfected with 10 μg of pcDNA6, Flag-C/EBPα, AA, AAA, or S230A mutants by the calcium phosphate method. DNA precipitant was added to cells for 4 h, prior to addition of inhibitors and hormones at the concentrations and for the times indicated in figure legends.

H4IIE cells were transfected as described previously [50]. Briefly, 10 μg of BP1-TIRE-Luc, the insulin insensitive point mutant of the TIRE (DM5-Luc), C/EBP-Luc, or pGL3-Luc (control), along with 1 μg of pcDNA6, wild type or mutant Flag-C/EBPα constructs were precipitated and incubated with H4IIE cells in suspension. Cells were plated onto 10 cm dishes, allowed to attach for 4 h, prior to DMSO shock and incubation with hormones/inhibitors for 20 h as indicated in figure legends. Cells were lysed in 200 μl lysis buffer (Promega, UK), the cell debris removed by centrifugation at 13,000 x g for 10 min at 4°C, and the supernatant stored at -70°C. Luciferase assays were performed using the firefly luciferase assay system (Promega, UK), according to manufacturer’s instructions, with luciferase activity being corrected for the protein concentration in the cell lysate.

3T3-L1 preadipocytes were transfected using Fugene 6 Transfection Reagent (Roche) following manufacturer’s protocol. C/EBP-Luc (2 μg) along with 200 ng of pcDNA6, wild type or mutant Flag-C/EBPα constructs was complexed with Fugene 6 transfection reagent prediluted in Serum Free DMEM at the ratio of 1:3 (μg DNA : μg Fugene 6) for 20 min at RT before addition to cells. After 4 h at 37°C an equal amount of DMEM containing 20% foetal calf serum was added. 48 h post-transfection, cells were washed with serum free DMEM and incubated for a further 24 h in serum free media with or without hormones or inhibitors as described in figure legends. Cells were lysed in 100 μl lysis buffer and luciferase activity determined as above.

We estimate that the level of over expression of C/EBPα is roughly 4 fold in the adipocytes, around 6 fold in the liver cells by transient transfection and nearly 10 fold in adenovirally infected H4IIE experiments.

**In vitro phosphorylation of C/EBPα**

Purified recombinant C/EBPα (6 pmol) was incubated at 30°C with His6-βGal-β-GSK3β (2 U/ml) or p42 MAPK (10 U/ml), 10 mM magnesium acetate, 0.1 mM γ-32P]ATP (450,000 cpm/nmol) in buffer containing 50 mM Tris-HCl, pH 7.5, 0.03% (v/v) Brij 35, and 0.1% (v/v) 2-mercaptoethanol, for times indicated in the figure legends. Reactions were stopped by the addition of LDS containing sample buffer (Novex), heated at 70°C for 10 min and subjected to SDS-PAGE. The gel was dried on the 3 M Filterpaper, and radiactivity incorporated into recombinant C/EBPα visualized by autoradiography and quantified by phosphorimager (Fuji). A standard curve of radiolabelled ATP was used to assess nmol of phosphate incorporated into the C/EBPα substrate. p42 MAP kinase and GSK3α activities were calculated by in vitro phosphorylation of myelin basic protein and P-GS peptide, respectively.

**Preparation of cell extract for SDS PAGE and Immunoblotting**

Cells were washed with ice cold PBS twice and scraped into ice-cold lysis buffer (25 mM Tris/HCl, pH 7.4, 50 mM NaF, 100 mM NaCl, 1 mM sodium vanadate, 5 mM EGTA, 1 mM EDTA, 1% (v/v) Triton X-100, 10 mM sodium pyrophosphate, 1 mM benzamidine, 0.1 mM PMSF, 0.27 M sucrose, 2 μM microcystin and 0.1% (v/v) 2-mercaptoethanol). Cell debris was removed by centrifugation at 13,000 x g for 10 min at 4°C. Preparation of nuclear protein extracts was performed using a Nuclear Extraction Kit (Panomics), as per the manufacture’s instructions. The protein concentration was determined by Bradford assay (Sigma), using BSA as standard as per the manufacture’s instructions. Protein from cell lines (10–20 μg from H4IIE, 50 μg from AD293 or 3T3 preadipocytes) was separated on Novex SDS 4–12% polyacrylamide gels. Following transfer to nitrocellulose, blots were blocked with 5% (w/v) non-fat milk in TBST (Tris-buffered saline containing 0.1% (v/v) Tween 20) for 1 h, and incubated with primary antibodies at 4°C overnight prior to incubation for 1 h at RT with the secondary antibody and development using ECL kit (Amersham Biosciences, Inc.).

**Adenoviral Infection, RNA extraction and RNase protection assay**

For RNA studies, H4IIE cells were infected with recombinant adenovirus expressing Flag-C/EBPα (Ad-C/EBPα) or β-Galactosidase (Ad-β-gal) for 4 h at MOI = 100. 24 h later, infected cells were split into 10 cm dishes and serum starved overnight prior to treatment with hormone/inhibitor for 3 h at the concentrations indicated in the figure legends. Total cellular RNA was isolated using TRI Reagent (Sigma) following the manufacturer’s instructions. An RNase Protection Assay (RPA) was performed to determine the relative amounts of IGFBP-1, G6Pase, and cyclophilin mRNA as described previously [50]. Band intensity was quantified on a phosphorimager (Fuji), data calculated as a ratio of IGFBP-1 to cyclophilin mRNA. For phosphorylation studies, H4IIE cells were infected with recombinant adenovirus expressing Flag-C/EBPα (Ad-C/EBPα) at MOI = 100. 16 h later, infected cells were serum starved for 3 h prior to treatment with hormone/inhibitor
for the times and at the concentrations indicated in the figure legends.

Statistics

The comparison of one variable between two groups was determined by unpaired Student’s t-test with the aid of PRISM 3.0 (Graphpad Software, USA) and/or Microsoft Excel. The values were expressed as mean ± S.E.M.

Abbreviations

PEPCK; Phosphoenolpyruvate Carboxykinase, IGFBP1; IGF binding protein-1, G6Pase; glucose-6-phosphatase, RPA; RNAase Protection Assay, TIRE; thymine rich insulin response element, C/EBP; CAAT enhancer binding protein, CBE; C/EBP binding element.

Authors’ contributions

The majority of the molecular work was performed by HKL, with important contributions from SP (adipocyte analysis, and phosphorylation time course), CL (endogenous gene transcription), and DF (adenoviral synthesis and production). Key reagents were produced to high quality by JH and HM. The project was conceived and jointly supervised by HSH and CS.

Acknowledgements

CL is a recipient of a BBSRC CASE studentship while CS is a recipient of the Diabetes UK Senior Fellowship (BDA:RD02/0002473). This work was primarily supported by Diabetes UK grant (BDA:RD03/0002583).

References

1. Frame S, Cohen P. GS3K takes cent stage more than 20 years after its discovery. Biochem j 2001, 359:1-16.
2. Embi N, Rylatt DB, Cohen P. Glycogen Synthase Kinase-3 from Rabbit Skeletal Muscle. Eur j Biochem 1980, 107(2):519-527.
3. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990, 9(8):2431-2438.
4. Woodgett JR. cDNA cloning and properties of GS3K. Meth Enzymol 1991, 200:564-577.
5. Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3β by phosphorylation; new kinase connections in insulin and growth factor signalling. Biochem J 1993, 296:15-19.
6. Sutherland C, Cohen P. The α-isoform of glycogen synthase kinase-3 from rabbit skeletal muscle is inactivated by p70 S6 kinase or MAP kinase-activated protein kinase-1 in vitro. FEBS Lett 1994, 338:37-42.
7. Farr GH, Ferkey DM, Yost C, Pierce SB, Weaver CD, Kimelman D: Interaction among GS3K-3, GBP, axin, and APC in Xenopus axis specification. J Cell Biol 2000, 148:691-702.
8. Cross DA, Aleks DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of GS3K by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
9. Arias AM, Brown AM, Brennan K. Wnt signalling: pathway or network? Curr Opin Genet Dev 1999, 9:447-454.
10. Lochhead PA, Coghlan MP, Rice SQJ, Sutherland C: Inhibition of GS3K selectively reduces G6Pase and PEYCCK gene expression. Diabetes 2001, 50:937-947.
11. Finlay D, Patel S, Dickson LM, Shiripo N, Marquez R, Rhodes CJ, Sutherland C: Glycogen Synthase Kinase-3 Regulates IGFBP1 Gene Transcription Through the Thymine-rich Insulin Response Element: Inhibition is required for full regulation of this promoter element by insulin. BMC Mol Biol 2004, 5:15.
12. O’Brien RM, Lucas PC, Forest CD, Magnanou MA, Granner DK: Identification of a sequence in the PEYCCK gene that mediates a negative effect of insulin on transcription. Science 1990, 249:533-537.
13. Suvanichkul A, Allander SV, Morris SL, Powell DR: Glucocorticoids and insulin regulate expression of the human gene for IGFBP-1 through proximal promoter elements. J Biol Chem 1994, 269(49):30835-30841.
14. Ayala JE, Streep RS, Desgrosellier JS, Durham SK, Suvanichkul A, Swidzinski CA, Goldman JM, Barr FG, Powell DR, O’Brien RM: Inhibition of an insulin response unit between mouse and human glucose-6-phosphatase catalytic subunit gene promoters: transcription factor FKHr binds the insulin response sequence. Diabetes 1999, 48(9):1885-1889.
15. Isomar K, Outiapiik M, Povoa G, Werner S, Hall K: Insulin regulates the 35 kDa IGF binding protein in patients with diabetes mellitus. J Endocrinol Invest 1988, 11(8):599-602.
16. Luo JM, Murphy LJ: Differential expression of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in the diabetic state. J Clin Endocrinol Metab 2000, 85:263-271.
17. Meijer L, Flajolet M, Greenberg P: Pharmacological inhibitors of GS3K-3. TIPS 2004, 25(9):471-480.
18. Hofmann C, Lorentz K, Williams D, Palaukz BJ, Colca JR: Insulin senitization in diabetic rat liver by an antihyperglycemic agent. Metabolism 1995, 44:384-389.
19. Nikouline SE, Ciardaldi TP, Mudalair S, Mohideen P, Carter L, Henry RR: Potential role of GS3K in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 2000, 49:263-271.
20. Meijer L, Flajolet M, Greenberg P: Effects of a novel GS3K inhibitor on insulin stimulated glucose metabolism in ZDF (fa/fa) rats. Diabetes 2002, 51:2903-2910.
21. Henrikson EJ, Kinrick TR, Teachey MK, O’Keefe MP, Ring D, Johnson KW, Harrison SD. Modulation of Muscle Insulin Resistance by Selective Inhibition of Glycogen Synthase Kinase 3 in Zucker Diabetic Fatty Rats. Am J Physiol Endocrinol Metab 2003, 285(1):E98-E105.
22. Ring DB, Johnson KW, Henrikson EJ, Nuss JM, Goff D, Kinrick TR, Ma ST, Reeder JW, Samuelis I, Slabiski T, et al: Selective GS3K inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003, 52(3):588-595.
23. Dokken BB, Sloniger JA, Henrikson EJ: Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in pre-diabetic skeletal muscle cells. Am J Physiol Endocrinol Metab 2005, 288(6):E188-E194.
24. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P: Down-regulation of b-catenin by human axin and its association with the APC tumour suppressor, b-catenin and GS3K3. Curr Biol 1998, 8:573-581.
25. Hoefflich KP, Luo J, Rubie EA, Tsao M, Jin O, Woodgett JR: Requirement for GS3Kbeta in cell survival and NFκB activation. Nature 2000, 406:88-90.
26. Ross SE, Erickson RL, Hemati N, MacDougald OA: Glycogen synthase kinase 1 is an insulin-regulated C/EBPalpha kinase. Mol Cell Biol 1999, 19(12):8433-8441.
27. Roseler WJ, Crosson SM, Vinson C, McFie PJ: The alpha-isoform of the CCAAT enhancer-binding protein is required for mediating cAMP responsiveness of the phosphoeno pyruvate carboxykinase gene promoter in hepatoma cells. J Biol Chem 1996, 271(14):8068-8074.
28. Croniger C, Trus M, Lysek-Stupp K, Cohen H, Liu Y, Darlington GJ, Poli V, Hanson RW, Reshlin L: Role of the isoforms of CCAAT enhancer-binding protein in the initiation of the phosphoenolpyruvate carboxykinase gene transcription at birth. J Biol Chem 1997, 272(42):26306-26312.
29. Yeagley D, Agati JM, Quinn PG: A tripartite array of transcription factor binding sites mediates cAMP induction of phosphoenolpyruvate carboxykinase gene transcription and its inhibition by insulin. J Biol Chem 1998, 273(30):18743-18750.
30. Crosson SM, Roseler WJ: Hormonal regulation of the phosphoenolpyruvate carboxykinase gene. Role of specific CCAAT/enhancer-binding protein isoforms. J Biol Chem 2000, 275(8):5804-5809.
33. Routes JM, Colton LA, Ryan S, Klemm Dj: CREB (cAMP response element binding protein) and C/EBPalpha (CCAT/enhancer binding protein) are required for the superstimulation of phosphoenolpyruvate carboxykinase gene transcription by adeno viral Eta and cAMP. Biochem J 2000, 352(Pt 2):335-342.

34. Jurado LA, Song S, Roesler WJ, Park EA: Conserved amino acids within CCAAT enhancer-binding proteins (CTEBP(alpha) and beta) regulate phosphoenolpyruvate carboxykinase (PEPCK) gene expression. J Biol Chem 2002, 277(31):27606-27612.

35. Kang S, Bajnok L, Longo KA, Petersen RK, Hansen JB, Kristiansen K, MacDougald OA: Effects of Wnt signaling on brown adipocyte differentiation and metabolism mediated by PGC-1alpha. Mol Cell Biol 2005, 25(4):1272-1282.

36. MacDougald OA, Cornelius P, Liu R, Lane MD: Insulin regulates transcription of the CCAAT/enhancer binding protein (C/EBP) alpha, beta, and delta genes in fully-differentiated 3T3-L1 adipocytes. J Biol Chem 1995, 270(2):647-654.

37. Valverde AM, Arribas M, Mur C, Navarro P, Pons S, Cassard-Doulcier AM, Kahn CR, Benito M: Insulin-induced up-regulated uncoupling protein-1 expression is mediated by insulin receptor substrate 1 through the phosphatidylinositol 3-kinase/Akt signaling pathway in fetal brown adipocytes. J Biol Chem 2003, 278(12):10221-10231.

38. Wang ND, Finegold MJ, Bradley A, Ou CN, Abdelsayed SV, Wilde MD, Taylor LR, Wilson DR, Darlington GJ: Impaired energy homeostasis in C/EBP alpha knockout mice. Science 1995, 269(5277):1108-1112.

39. Lee YH, Sauer B, Johnson PF, Gonzalez FJ: Disruption of the c/ebp alpha gene in adult mouse liver. Mol Cell Biol 1997, 17(10):6014-6022.

40. Yang J, Croniger JM, Lekstrom-Himes J, Zhang P, Fenyes M, Tenen DG, Darlington GJ, Hanson RW: Metabolic response of mice to a postnatal ablation of CCAAT/enhancer-binding protein alpha (C/EBPalpha). J Biol Chem 2005, M503486200.

41. Untermann T, Oehler D, Nguyen H, Sengupta P, Laco RN: A novel DNA/protein complex interacts with the insulin-like growth factor binding protein-1 (IGFBP-1) insulin response sequence and is required for maximal effects of insulin and glucocorticoids on promoter function. Prog Growth Factor Res 1995, 6(2-4):119-129.

42. Hall RK, Yamasaki T, Kucer T, Walner-Law M, O'Brien RM, Grainemier DK: Regulation of Phosphoenolpyruvate Carboxykinase and Insulin-like Growth Factor-binding Protein-1 Gene Expression by Insulin. THE ROLE OF WINGED HELIX/FOREHEAD PROTEINS. J Biol Chem 2000, 275(30):26931-26937.

43. Murray JT, Campbell DG, Morrice N, Auld GC, Shpiro N, Marquez R, Peggie M, Bain J, Bloomerg GB, Grahammer F, et al: Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem J 2004, 384(3):477-488.

44. Ross SE, Radomska HS, Wu B, Zhang P, Winnay JN, Bajnok L, Wright WS, Schaufele F, Tenen DG, MacDougald OA: Phosphorylation of C/EBPalpha inhibits granulopoiesis. Mol Cell Biol 2004, 24(2):675-686.

45. Cole A, Knebel A, Morrice NA, Robertson LS, Irving AJ, Connolly CN, Sutherland C: GSK-3 phosphorylation of the Alzheimers epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J Biol Chem 2004, 279(48):50176-50180.

46. Macaulay K, Hajduk E, Blair AS, Coghlan MP, Smith SA, Hundal HS: Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase. Eur J Biochem 2003, 270(18):3829-3838.

47. Darlington GJ, Ross SE, MacDougald OA: The role of C/EBP genes in adipocyte differentiation. J Biol Chem 1998, 273(46):30057-30060.

48. Park BH, Qiang L, Farmer SR: Phosphorylation of C/EBPbeta at a consensus extracellular signal-regulated kinase/glycogen synthase kinase 3 site is required for the induction of adiponectin gene expression during the differentiation of mouse fibroblasts into adipocytes. Mol Cell Biol 2004, 24(19):8671-8680.

49. Tang QQ, Gronborg M, Huang H, Kim JW, Otto TC, Pandey A, Lane MD: Sequential phosphorylation of CCAAT enhancer-bind-

50. Patel S, Lochhead PA, Rena G, Fumagalli S, Pende M, Kozma S, Thomas GM, Sutherland C: Insulin regulation of IGF-binding protein-I gene expression is dependent on mammalian target of rapamycin (mTOR), but independent of S6K activity. J Biol Chem 2002, 277(12):9889-9895.